Alumis’ (ALMS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alumis (NASDAQ:ALMS) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $26.00 price objective on the stock.

A number of other analysts have also issued reports on the stock. Robert W. Baird began coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $26.83.

Alumis Trading Down 4.5 %

NASDAQ:ALMS opened at $7.69 on Monday. The company’s fifty day simple moving average is $9.26. Alumis has a 1-year low of $7.46 and a 1-year high of $13.53.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALMS. Samsara BioCapital LLC bought a new stake in Alumis in the third quarter worth $34,886,000. SR One Capital Management LP bought a new stake in shares of Alumis during the 2nd quarter worth about $26,067,000. Yu Fan acquired a new position in shares of Alumis during the 2nd quarter valued at about $10,502,000. Ally Bridge Group NY LLC bought a new position in shares of Alumis in the 2nd quarter valued at approximately $8,229,000. Finally, Towerview LLC lifted its holdings in Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after purchasing an additional 70,000 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.